Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag Protein, CF

Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag Protein (Catalog # 10613-ER) blocks anti-ErbB2 mediated inhibition of the SK-BR-3 human breast cancer cell line proliferation. The ED50 is 0.7-7 μg/mL in the presence of 0.6 μg/mL Trastuzumab (Human ErbB2/Her2 Antibody, MAB9589).

2 μg/lane of Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag (Catalog # 10613-ER) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 95-110 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to block anti-ErbB2 mediated inhibition of SK‑BR‑3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED₅₀ for this effect is 0.7-7 μg/mL in the presence of 0.6 µg/mL Human ErbB2/Her2 Antibody (Trastuzumab, Catalog # MAB9589).
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey ErbB2/Her2 protein
  Thr23-Thr652, with a C-terminal 6-His tag
• Accession #: XP_005584091.2
• N-terminal Sequence: Thr23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 70 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95-110 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag Protein, CF

• CD340 antigen
• CD340
• c-erb B2/neu protein
• EC 2.7.10
• EGFR2
• ErbB2
• HER2
• HER-2
• HER2EC 2.7.10.1
• herstatin
• Metastatic lymph node gene 19 protein
• MLN 19
• MLN19
• Neu Oncogene
• NEUHER-2/neu
• neuroblastoma/glioblastoma derived oncogene homolog
• NGL
• NGLTKR1
• p185erbB2
• Proto-oncogene c-ErbB-2
• Proto-oncogene Neu
• receptor tyrosine-protein kinase erbB-2
• TKR1
• Tyrosine kinase-type cell surface receptor HER2
• v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog)
• v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)

Background

ErbB2, also called human epidermal growth factor receptor 2 (HER2) and Neu, is a type I membrane glycoprotein and is one of four members of the ErbB family of receptor tyrosine kinases. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. Cynomolgus ErbB2 consists of an extracellular domain (ECD) with two ligand binding domains and two cystine rich domains, a transmembranee region and a cytoplasmic domain with a flexible juxtamembrane region followed by a protein kinase domain (1). The ECD of mature cynomolgus ErbB2 shares 99% amino acid sequence identity with the ECD of human ErbB2. ErbB2 signaling is associated with neurodegenerative diseases such as multiple sclerosis and Alzheimer disease when impaired, while over-expression of ErbB2 signaling is associated with development of cancers (2). ErbB2 is widely expressed in epithelial cells and has been primarily associated with breast carcinomas (3, 4). Over-expression of HER-2 also caused other cancers such as gastric (2,5), colorectal (6), ovary, lung, bladder, head and neck (7), and osteosarcoma (8). Among ErbB family members, ErbB2 is unique in that it has no identified ligands. Rather, ErbB2 heterodimerizes with the other members of the ErbB family to form higher affinity signaling complexes (9). ErbB2 can be shed from the cell surface by the protease ADAM10, resulting in a constitutively active truncated intracellular receptor (10). ERBB2 is used as biomarkers in several cancers and is an attractive oncogenic driver and therapeutic target in cancers (6).

1. Ferguson, K.M. (2008) Annu Rev Biophys. 37:353.
2. Boku, N. (2014) Gastric Cancer. 17:1.
3. Harari, D. and Yarden, Y. (2000) Oncogene 19:6102.
4. Bertucci, F. et al. (2004) Oncogene 23:2564
5. Palle J. et al. (2020) Drug 80(4):401.
6. De Cuyper, A. et al. (2020) Clin Colorectal Cancer. 19(2):65.
7. Vats, S. et al. (2018) Indian Journal Pathology & Microbiology.
8. Hughes, D.P. et al. (2004) Cancer Res 64(6):2047.
9. Citri, A. et al. (2003) Exp Cell Res. 284:54.
10. Liu, P.C. et al. (2006) Cancer Biol Ther. 5:657.

FAQs for ErbB2/Her2 (10613-ER). (Showing 1 - 1 of 1 FAQ).

1. I am interested in getting antibodies for HER that would work in flow cytometry. Could you recommend some choices?
   • A list of our ErbB2 antibodies validated for use in flow cytometry can be found here /productsearch/HER2#fq=common_name%3A%22ErbB2%2FHER2%22&fq=category%3A%22Primary%20Antibodies%22&fq=applications%3A%22Flow%20Cytometry%22

Bioinformatics

• Uniprot:
  • XP_005584091.2()